unfortunatelyUnfortunately, I expect a disappointing Q2 relative to the feeling I had going into Q2. Further I think the market also expects this, which is reflected in the share price. Here is why:
- No Plexxus deal in Q2. Unthinkable. at the end of Q1
- I dont expect large sales numbers of VTM in Q2, based on the AGM. There will be some incremental sales for sure, but not to the level we expected at the end of Q1. This goes hand in hand with the lack of a Plexxus deal.
- I think antigen sales will be about where they were in Q1, as the Pandemic continues to rage on, and it is hard to see how anything great will have happened.
- QAP's will likely increase over Q1 and possibly materially. However, even an extra 1m in the quarter would be a great acheivement. So......In a perfect world I see top line revenue as follows:
Antigens 2.5m
VTM .5 m
Qaps 1.5 m
Total 4.5 m
I understand this would be a very significant increase over the past and a huge achievement in the development of the company. But it may not be the homerun quarter that everyone is hoping for.
If I am right, and I hope I am not, then the Plexxus deal or a Kinlytic deal are the only real short term catalysts for share price appreciation. I have confidence in the company and the direction, but we may languish at these prices for another quarter.
Does anyone else have bolder predictions?